Symbols

NVAX

Novavax·NASDAQ

--(--)

NVAX fundamentals

NVAX Q4 2025 Earnings

Novavax (NVAX) released its earnings on Feb 26, 2026: revenue was 147.14M (YoY +66.61%), beat estimates; EPS was 0.11 (YoY +121.57%), beat estimates.

Revenue / YoY

147.14M

+66.61%

EPS / YoY

0.11

+121.57%

Report date

Feb 26, 2026

NVAX Earnings Call Summary for Q4,2025

Revenue milestone: $1.1B in 2025, up 65% YoY, with $800M+ in non-dilutive capital from partnerships.
Matrix-M expansion: 2 new disease areas with Pfizer, oncology MTA signed, and $200M+ per-partner royalty potential.
Pipeline progress: C. diff vaccine IND targeting 2027, shingles/RSV combo candidates in preclinical stages.
Cost efficiency: 42% YoY expense reduction, $200M 2028 run rate target, and $857M cash at year-end.
Sanofi combo vaccine: $125M Phase III milestone at risk, with 2026 flu/COVID launch expected.

Earnings

EPS

Revenue

Revenue & Expenses

NVAX has released its 2025 Q4 earnings report, with revenue of 147.14M, reflecting a YoY change of 66.61%, and net profit of 17.53M, showing a YoY change of 121.63%. The Sankey diagram below clearly presents NVAX's revenue sources and cost distribution.

Key Indicators

Novavax (NVAX) key financial stats and ratios, covering profitability, financial health, and leverage.

Income Statement

Novavax (NVAX)'s revenue and profit trends over recent years, visualized with a waterfall chart to showcase the revenue-to-profit funnel.

Trend

Breakdown

Balance Sheet

Novavax (NVAX)'s asset and liability trends over recent years, visualized with a waterfall chart to illustrate changes in its asset-liability structure.

Trend

Breakdown

Cash Flow

Novavax (NVAX)'s cash flow trends over recent years, visualized with a waterfall chart to illustrate changes in its operating, investing, and financing cash flows.

Trend

Breakdown